Frazier Life Sciences IX, L.P. 4
4 · Phathom Pharmaceuticals, Inc. · Filed Oct 30, 2019
Insider Transaction Report
Form 4
Frazier Life Sciences IX, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2019-10-29$19.00/sh+1,052,631$19,999,989→ 7,284,269 total - Conversion
Common Stock
2019-10-29$15.20/sh+1,353,640$20,575,328→ 6,231,638 total - Conversion
Convertible Promissory Notes
2019-10-29→ 0 totalExp: 2020-05-07→ Common Stock (1,353,640 underlying)
Footnotes (2)
- [F1]Immediately prior to the closing of the Issuer's initial public offering, the outstanding principal and unpaid accrued interest due on the Convertible Promissory Notes automatically converted into shares of the Issuer's Common Stock based on a conversion price of $15.20 per share.
- [F2]The shares reported herein are held of record by Frazier Life Sciences IX, L.P. ("FLS IX"). The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr. Topper and Mr. Heron disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.